Sanofi Tops Pfizer As Number One For Global Pharma Sales

08-Nov-2011 - United Kingdom

EvaluatePharma Ltd revealed that Sanofi is expected to take the top spot amongst the world’s pharmaceuticals manufacturers in 2012 and hold it through 2016. The French drug maker has raced up the rankings over the last decade largely through M&A activity, with the $20bn purchase this year of US biotechnology specialist Genzyme predicted to help win its number one ranking.

“The takeover of Genzyme, an aggressive cross-border move, revealed just how much the culture of Sanofi has changed in the last few years,” commented Dr Jonathan de Pass, chief executive of EvaluatePharma.  “Coming just as Pfizer loses Lipitor, the acquisition should be enough to secure Sanofi the top spot for the next few years, our data suggest.”

Market Rank


Rx & OTC pharma sales ($bn)


2011 2012 2014 2016 2011 2012 2014 2016 Annual growth

2011-16

Sanofi 3 1 1 1 47.9 51.6 55.4 58.4 4%
Novartis 2 2 2 2 49.5 49.9 52.2 54.8 2%
Pfizer 1 3 3 3 54.1 49.8 49.7 51.9 (1%)
GlaxoSmithKline 5 6 5 4 39.3 41.2 45.6 50.9 5%
Roche 6 4 4 5 39.1 44.1 46.3 49.0 5%
Merck & Co 4 5 6 6 42.1 41.9 41.4 43.4 1%
Johnson & Johnson 8 8 7 7 24.8 26.5 29.4 31.5 5%
AstraZeneca 7 7 8 8 32.0 29.2 27.5 25.7 (4%)
Teva 12 10 10 9 17.4 20.3 22.5 24.4 7%
Abbott Laboratories 9 9 9 10 22.5 23.5 23.7 24.3 2%
Bayer 11 12 11 11 18.9 19.7 21.7 23.4 4%
Takeda 14 13 12 12 17.0 18.2 18.7 20.2 3%
Bristol-Myers Squibb 13 16 17 13 17.1 14.2 15.4 18.9 2%
Novo Nordisk 17 17 15 14 12.3 13.6 16.4 18.9 9%
Eli Lilly 10 11 14 13 21.5 20.1 17.6 17.9 (4%)

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances